- Conditions
- Platinum-resistant Epithelial Ovarian Cancer
- Interventions
- Maveropepimut-S, Cyclophosphamide 50mg
- Other · Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
- Interventions
- DPX-Survivac, Pembrolizumab, CPA
- Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Boca Raton, Florida • Hollywood, Florida + 13 more